Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
Open Access
- 3 July 2020
- journal article
- letter
- Published by Elsevier BV in Kidney International Reports
- Vol. 5 (9), 1515-1518
- https://doi.org/10.1016/j.ekir.2020.06.030
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 CasesAmerican Journal of Kidney Diseases, 2020
- Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With RituximabFrontiers in Immunology, 2020
- Rituximab or Cyclosporine in the Treatment of Membranous NephropathyThe New England Journal of Medicine, 2019
- Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplantAmerican Journal of Transplantation, 2019
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsThe New England Journal of Medicine, 2014
- Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsBritish Journal of Haematology, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyThe New England Journal of Medicine, 2009
- Prognosis of Untreated Patients with Idiopathic Membranous NephropathyThe New England Journal of Medicine, 1993